Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 46
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Addy, Carol Tatosian, Daniel Glasgow, Xiaoli S. Gendrano, Isaias N. Kauh, Eunkyung Martucci, Ashley Johnson-Levonas, Amy O. Selverian, Diana Matthews, Catherine Z. Gutierrez, Marie Wagner, John A. and Aubrey Stoch, S. 2016. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus. Clinical Therapeutics, Vol. 38, Issue. 3, p. 516.

    Anderberg, Rozita H Richard, Jennifer E Hansson, Caroline Nissbrandt, Hans Bergquist, Filip and Skibicka, Karolina P. 2016. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology, Vol. 65, p. 54.

    Broichhagen, Johannes Johnston, Natalie R. von Ohlen, Yorrick Meyer-Berg, Helena Jones, Ben J. Bloom, Stephen R. Rutter, Guy A. Trauner, Dirk and Hodson, David J. 2016. Allosteric Optical Control of a Class B G-Protein-Coupled Receptor. Angewandte Chemie International Edition, Vol. 55, Issue. 19, p. 5865.

    Broichhagen, Johannes Johnston, Natalie R. von Ohlen, Yorrick Meyer-Berg, Helena Jones, Ben J. Bloom, Stephen R. Rutter, Guy A. Trauner, Dirk and Hodson, David J. 2016. Allosterische optische Steuerung eines Klasse-B-G-Protein-gekoppelten Rezeptors. Angewandte Chemie, Vol. 128, Issue. 19, p. 5961.

    Holst, Jens Juul 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes.

    Mazzawi, T Hausken, T Gundersen, D and El-Salhy, M 2016. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. European Journal of Clinical Nutrition, Vol. 70, Issue. 2, p. 175.

    Svendsen, Berit and Holst, Jens Juul 2016. Regulation of gut hormone secretion. Studies using isolated perfused intestines. Peptides, Vol. 77, p. 47.

    Tomlinson, Brian Hu, Miao Zhang, Yuzhen Chan, Paul and Liu, Zhong-Min 2016. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs, Vol. 25, Issue. 2, p. 145.

    Mazzawi, Tarek Gundersen, Doris Hausken, Trygve and El-Salhy, Magdy 2015. Increased Chromogranin A Cell Density in the Large Intestine of Patients with Irritable Bowel Syndrome after Receiving Dietary Guidance. Gastroenterology Research and Practice, Vol. 2015, p. 1.

    Delfino, Marcello Motola, Domenico Benini, Angela Franzè, Gian Pietro Barotto, Marcella Campi, Anna and Monda, Vincenzo Maria 2014. Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy. Expert Opinion on Drug Safety, Vol. 13, Issue. 2, p. 151.

    Isackson, Henrik and Ashley, Christopher C. 2014. Secretory functions of the gastrointestinal tract. Surgery (Oxford), Vol. 32, Issue. 8, p. 396.

    Ezcurra, Marina Reimann, Frank Gribble, Fiona M and Emery, Edward 2013. Molecular mechanisms of incretin hormone secretion. Current Opinion in Pharmacology, Vol. 13, Issue. 6, p. 922.

    Holst, Jens Juul and Deacon, Carolyn F. 2013. Is there a place for incretin therapies in obesity and prediabetes?. Trends in Endocrinology & Metabolism, Vol. 24, Issue. 3, p. 145.

    Holst, Jens Juul Bolette Hartmann, Carolyn F. Deacon and Pedersen, Jens 2013. Handbook of Biologically Active Peptides.

    Reusch, Claudia E. and Padrutt, Isabelle 2013. New Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats. Veterinary Clinics of North America: Small Animal Practice, Vol. 43, Issue. 2, p. 417.

    Young, R. L. Chia, B. Isaacs, N. J. Ma, J. Khoo, J. Wu, T. Horowitz, M. and Rayner, C. K. 2013. Disordered Control of Intestinal Sweet Taste Receptor Expression and Glucose Absorption in Type 2 Diabetes. Diabetes, Vol. 62, Issue. 10, p. 3532.

    Zambrowicz, Brian Ding, Zhi-Ming Ogbaa, Ike Frazier, Kenny Banks, Phillip Turnage, Anne Freiman, Joel Smith, Melinda Ruff, Dennis Sands, Arthur and Powell, David 2013. Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics, Vol. 35, Issue. 3, p. 273.

    Blaak, E. E. Antoine, J.-M. Benton, D. Björck, I. Bozzetto, L. Brouns, F. Diamant, M. Dye, L. Hulshof, T. Holst, J. J. Lamport, D. J. Laville, M. Lawton, C. L. Meheust, A. Nilson, A. Normand, S. Rivellese, A. A. Theis, S. Torekov, S. S. and Vinoy, S. 2012. Impact of postprandial glycaemia on health and prevention of disease. Obesity Reviews, Vol. 13, Issue. 10, p. 923.

    Blad, Clara C. Tang, Cong and Offermanns, Stefan 2012. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery, Vol. 11, Issue. 8, p. 603.

    Hansen, Harald S. Rosenkilde, Mette M. Holst, Jens J. and Schwartz, Thue W. 2012. GPR119 as a fat sensor. Trends in Pharmacological Sciences, Vol. 33, Issue. 7, p. 374.

  • Expert Reviews in Molecular Medicine, Volume 12
  • 2010, e1

Molecular mechanisms underlying nutrient-stimulated incretin secretion

  • Helen E. Parker (a1), Frank Reimann (a1) and Fiona M. Gribble (a1)
  • DOI:
  • Published online: 05 January 2010

The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from enteroendocrine cells in the intestinal epithelium in response to nutrient ingestion. The actions of GLP-1 and GIP – not only on local gut physiology but also on glucose homeostasis, appetite control and fat metabolism – have made these hormones an attractive area for drug discovery programmes. The potential range of strategies to target the secretion of these hormones therapeutically has been limited by an incomplete understanding of the mechanisms underlying their release. The use of organ and whole-animal perfusion techniques, cell line models and primary L- and K-cells has led to the identification of a variety of pathways involved in the sensing of carbohydrate, fat and protein in the gut lumen. This review focuses on our current understanding of these signalling mechanisms that might underlie nutrient responsiveness of L- and K-cells.

Corresponding author
*Corresponding author: Fiona M. Gribble, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1W. Creutzfeldt (2005) The [pre-] history of the incretin concept. Regulatory Peptides 128, 87-91

2B. Moore , E.S. Edie and J.H. Abram (1906) On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochemical Journal 1, 28-38

3J.F. Rehfeld (2004) A centenary of gastrointestinal endocrinology. Hormone and Metabolic Research 36, 735-741

4H Elrick . (1964) Plasma insulin response to oral and intravenous glucose administration. Journal of Clinical Endocrinology and Metabolism 24, 1076-1082

5W. Creutzfeldt (1979) The incretin concept today. Diabetologia 16, 75-85

6L. Baggio and D. Drucker (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157

8J. Gromada , J.J. Holst and P. Rorsman (1998) Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Archiv (European Journal of Physiology) 435, 583-594

9R. Eissele (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation 22, 283-291

10J.M. Polak (1973) Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum. Gut 14, 284-288

11A.M. Buchan (1978) Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 56, 37-44

12C. Herrmann (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56, 117-126

13S. Cataland (1974) Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. Journal of Clinical Endocrinology and Metabolism 39, 223-228

14R.M. Elliott (1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. Journal of Endocrinology 138, 159-166

15H.J. Balks (1997) Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. Journal of Clinical Endocrinology and Metabolism 82, 786-790

16J. Schirra (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. Journal of Clinical Investigation 97, 92-103

17L. Hansen and J.J. Holst (2002) The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regulatory Peptides 110, 39-45

18A.S. Rocca and P.L. Brubaker (1999) Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140, 1687-1694

19K. Mortensen (2003) GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regulatory Peptides 114, 189-196

20M.J. Theodorakis (2006) Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. American Journal of Physiology, Endocrinology and Metabolism 290, 550-559

22C. Orskov , A. Wettergren and J.J. Holst (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42, 658-661

23J.J. Meier and M.A. Nauck (2005) Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews 21, 91-117

24L.L. Baggio (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546-558

25M.R. Druce (2009) Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150, 1712-1722

26R. Ugleholdt (2006) Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. Journal of Biological Chemistry 281, 11050-11057

27H. Demuth , C. McIntosh and R. Pederson (2005) Type 2 diabetes–therapy with dipeptidyl peptidase IV inhibitors. Biochimica et Biophysica Acta 1751, 33-44

28L. Hansen (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140, 5356-5363

29R. Mentlein (1999) Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regulatory Peptides 85, 9-24

30C.F. Deacon (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism 85, 3575-3581

31T.J. Kieffer , C.H. McIntosh and R.A. Pederson (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596

32T.P. Vahl (2007) Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148, 4965-4973

33V. Bucinskaite (2009) Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterology and Motility 21, 978-e78

34A. Nakagawa (2004) Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Autonomic Neuroscience 110, 36-43

35M. Kakei (2002) Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. Autonomic Neuroscience 102, 39-44

36S.M. Simasko and R.C. Ritter (2003) Cholecystokinin activates both A- and C-type vagal afferent neurons. American Journal of Physiology – Gastrointestinal and Liver Physiology 285, G1204-1213

37S.M. Simasko (2002) Cholecystokinin increases cytosolic calcium in a subpopulation of cultured vagal afferent neurons. American Journal of Physiology – Regulatory Integrative and Comparative Physiology 283, R1303-1313

38D.L. Williams , D.G. Baskin and M.W. Schwartz (2009) Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150, 1680-1687

39D. Drucker (1994) Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Molecular Endocrinology 8, 1646-1655

42E.B. Ramshur , T.R. Rull and B.M. Wice (2002) Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo. Journal of Cellular Physiology 192, 339-350

43A.T. Cheung (2000) Glucose-dependent insulin release from genetically engineered K cells. Science 290, 1959-1962

45R.A. Reimer (2001) A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142, 4522-4528

46X. Cao (2003) Aberrant regulation of human intestinal proglucagon gene expression in the NCI-H716 cell line. Endocrinology 144, 2025-2033

47P.L. Brubaker and M. Vranic (1987) Fetal rat intestinal cells in monolayer culture: a new in vitro system to study the glucagon-like immunoreactive peptides. Endocrinology 120, 1976-1985

49A.B. Damholt , A.M. Buchan and H. Kofod (1998) Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology 139, 2085-2091

50F. Reimann (2008) Glucose sensing in L cells: a primary cell study. Cell Metabolism 8, 532-539

51H.E. Parker (2009) Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52, 289-298

52F. Reimann and F.M. Gribble (2002) Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51, 2757-2763

53L.B. Nielsen (2007) Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. European Journal of Endocrinology 156, 663-671

54F. Matschinsky (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51, 394-404

55B. Glaser (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. New England Journal of Medicine 338, 226-230

56M. Stoffel (1992) Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes. Nature Genetics 2, 153-156

58A. El-Ouaghlidi (2007) The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. Journal of Clinical Endocrinology and Metabolism 92, 4165-4171

59R. Murphy (2009) Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor. Diabetologia 52, 154-159

60T. Miki (2005) Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 54, 1056-1063

61K. Vollmer (2009) Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. Journal of Clinical Endocrinology and Metabolism 94, 1379-1385

62L. Hansen (2004) Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regulatory Peptides 118, 11-18

63S. Sykes (1980) Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. Journal of Endocrinology 85, 201-207

64F.M. Gribble (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52, 1147-1154

65U. Ritzel (1997) Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetologica 34, 18-21

67J.A. Gonzalez , F. Reimann and D. Burdakov (2009) Dissociation between sensing and metabolism of glucose in sugar sensing neurones. Journal of Physiology 587, 41-48

68A. Diez-Sampedro (2000) Glycoside binding and translocation in Na+-dependent glucose cotransporters: comparison of SGLT1 and SGLT3. Journal of Membrane Biology 176, 111-117

69H.J. Jang (2007) Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proceedings of the National Academy of Sciences of the United States of America 104, 15069-15074

70E. Rozengurt and C. Sternini (2007) Taste receptor signaling in the mammalian gut. Current Opinion in Pharmacology 7, 557-562

71J. Dyer (2005) Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochemical Society Transactions 33, 302-305

72S.V. Wu (2002) Expression of bitter taste receptors of the T2R family in the gastrointestinal tract and enteroendocrine STC-1 cells. Proceedings of the National Academy of Sciences of the United States of America 99, 2392-2397

73N. Rozengurt (2006) Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon. Amerian Journal of Physiology – Gastrointestinal and Liver Physiology 291, G792-802

74Y. Fujita (2009) Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. American Journal of Physiology – Endocrinology and Metabolism 296, E473-479

75T.J. Little (2009) Sweetness and bitterness taste of meals per se does not mediate gastric emptying in humans. American Journal of Physiology – Regulatory Integrative and Comparative Physiology 297, R632-639

76J. Ma (2009) Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. American Journal of Physiology – Gastrointestinal and Liver Physiology 296, G735-739

77C. Bezencon , J. le Coutre and S. Damak (2007) Taste-signaling proteins are coexpressed in solitary intestinal epithelial cells. Chemical Senses 32, 41-49

78M.C. Chen (2006) Bitter stimuli induce Ca2+ signaling and CCK release in enteroendocrine STC-1 cells: role of L-type voltage-sensitive Ca2+ channels. American Journal of Physiology – Cell Physiology 291, C726-739

79C.D. Dotson (2008) Bitter taste receptors influence glucose homeostasis. PLoS ONE 3, e3974

81A. Saraya (2004) Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. European Journal of Pharmacology 497, 111-117

82E. Nemoz-Gaillard (1998) Regulation of cholecystokinin secretion by peptones and peptidomimetic antibiotics in STC-1 cells. Endocrinology 139, 932-938

83M. Cordier-Bussat (1998) Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 47, 1038-1045

84R.A. Reimer (2006) Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. Journal of Endocrinology 191, 159-170

85K. Matsumura (2005) Possible role of PEPT1 in gastrointestinal hormone secretion. Biochemical and Biophysical Research Communications 336, 1028-1032

86A. Gameiro (2005) The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. Journal of Physiology 569, 761-772

87F. Reimann (2004) Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47, 1592-1601

88J.R. Greenfield (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. American Journal of Clinical Nutrition 89, 106-113

89V. Dumoulin (1998) Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139, 3780-3786

90A. Pilichiewicz (2003) Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 88, 3829-3834

91F.Y. Enc (2009) Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. American Journal of Physiology – Gastrointestinal and Liver Physiology 296, G482-489

92M. Ellrichmann (2008) Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. Journal of Clinical Endocrinology and Metabolism 93, 3995-3998

93R. Iakoubov (2007) Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148, 1089-1098

94A. Simpson (2007) Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 50, 2181-2189

95P.L. Brubaker (1988) Control of glucagon-like immunoreactive peptide secretion from fetal rat intestinal cultures. Endocrinology 123, 220-226

96A.M. Buchan (1987) Morphologic and physiologic studies of canine ileal enteroglucagon-containing cells in short-term culture. Gastroenterology 93, 791-800

97P.L. Brubaker , J. Schloos and D.J. Drucker (1998) Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139, 4108-4114

98J.N. Roberge and P.L. Brubaker (1993) Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133, 233-240

99H.A. Overton (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metabolism 3, 167-175

100H. Lan (2009) GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. Journal of Endocrinology 201, 219-230

101Z.L. Chu (2008) A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149, 2038-2047

102Y. Kawamata (2003) A G protein-coupled receptor responsive to bile acids. Journal of Biological Chemistry 278, 9435-9440

103C.W. le Roux (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 246, 780-785

104M.E. Patti (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17, 1671-1677

106S. Katsuma , A. Hirasawa and G. Tsujimoto (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochemical and Biophysical Research Communications 329, 386-390

107J. Abello (1994) Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. Endocrinology 134, 2011-2017

108J.N. Roberge , K.A. Gronau and P.L. Brubaker (1996) Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137, 2383-2388

109Y. Anini , T. Hansotia and P.L. Brubaker (2002) Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143, 2420-2426

110F. Reimann , P.S. Ward and F.M. Gribble (2006) Signalling mechanisms underlying the release of glucagon-like peptide-1. Diabetes 55, S78-S85

111T. Tanaka (2008) Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn-Schmiedeberg's Archives of Pharmacology 377, 523-527

112A. Hirasawa (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature Medicine 11, 90-94

113S. Edfalk , P. Steneberg and H. Edlund (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57, 2280-2287

114T. Tanaka (2008) Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn-Schmiedeberg's Archives of Pharmacology 377, 515-522

115J. Wang (2006) Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. Journal of Biological Chemistry 281, 34457-34464

117S. Karaki (2006) Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell and Tissue Research 324, 353-360

118P. Plaisancie (1995) Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. Journal of Endocrinology 145, 521-526

119W.E. Longo (1991) Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. Scandinavian Journal of Gastroenterology 26, 442-448

120D.K. Covington (2006) The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochemical Society Transactions 34, 770-773

122M.A. Nauck (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741-744

123D.J. Drucker and M.A. Nauck (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 368, 1696-1705

124S.F. Grant (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 38, 320-323

125S.A. Schafer (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50, 2443-2450

126H. Unoki (2008) SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nature Genetics 40, 1098-1102

127K. Mussig (2009) Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 58, 1715-1720

128G. Yip and M. Wolfe (1999) GIP biology and fat metabolism. Life Sciences 66, 91-103

129R.G. Yip (1998) Functional GIP receptors are present on adipocytes. Endocrinology 139, 4004-4007

130R.H. Eckel , W.Y. Fujimoto and J.D. Brunzell (1979) Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 28, 1141-1142

132M.C. Althage (2008) Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. Journal of Biological Chemistry 283, 18365-18376

133P.L. McClean (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American Journal of Physiology – Endocrinology and Metabolism 293, E1746-1755

134M. Nauck (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 91, 301-307

135Y. Rouillé , S. Martin and D.F. Steiner (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. Journal of Biological Chemistry 270, 26488–16496

J.J. Holst (2007) The physiology of glucagon-like peptide 1. Physiological Reviews 87, 1409-1439

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *